Emile Voisine

Emile Voisine

Auto-generated profile, based on publicly available information

Emile Voisine

Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Québec City, Québec, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
EVEmile Voisine
Emile Voisine
FBFrédéric Beaupré
Frédéric Beaupré
KOKim O'COnnor
Kim O'COnnor
MMMohammed Marzouk
Mohammed Marzouk
JBJonathan Beaudoin
Jonathan Beaudoin
MSMario Senechal
Mario Senechal

15 March 2024 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Open access
EVEmile Voisine
Emile Voisine
SLSylvain Lemay
Sylvain Lemay
JBJonathan Beaudoin
Jonathan Beaudoin
PJPhilippe Jacob
Philippe Jacob
FPFrançois Philippon
François Philippon
MSMario Sénéchal
Mario Sénéchal
A 40‐year‐old man, newly diagnosed with cardiac sarcoidosis (CS) presented with symptomatic ventricular tachycardia three days after starting steroid‐based immunosuppressive therapy (IT). There was no clear guideline indication for implantable cardioverter‐defibrillator (ICD) before the initiation of IT. Shortly after ICD implantation and the initiation of anti‐arrhythmic drugs, recurring ventricular arrhythmias required titration of the anti‐arrhythmic drug therapy. One‐year follow‐up assessment showed no significant arrhythmias and complete PET scan FDG uptake suppression. This case, along with recent publications, suggests transient pro‐arrhythmic effects of steroids in patients with CS, which are not appropriately addressed in the current guidelines. We believe ICD implantation should be considered in clinically manifest CS before initiating IT, particularly in cases with heterogeneous and/or extensive FDG uptake on PET scans.

15 July 2025 in CJC Open
Verified
Journal Article
Open access
JLJean-Simon Lalancette
Jean-Simon Lalancette
ABAlexander Beaulieu-Shearer
Alexander Beaulieu-Shearer
ÉVÉmile Voisine
Émile Voisine
MLMaxime Laflamme
Maxime Laflamme
DBDavid Belzile
David Belzile
MSMario Senechal
Mario Senechal
In some patients with left ventricular assist devices (LVADs), unloading of the left ventricle (LV) and medical therapy may lead to improvement in LV systolic function, allowing for LVAD weaning. There are no guideline-directed parameters to help identify candidates for weaning and long-term outcomes remain imperfectly documented. In this study we aimed to assess the clinical and echocardiographic characteristics of weaned patients and evaluate their event-free survival after weaning. This investigation was a single-center retrospective study of patients who underwent a second- or third-generation LVAD implantation between 2009 and 2021. Ninety-eight patients were included. Fourteen patients (14%) with LV recovery underwent LVAD weaning after a median support time of 309 days. Heart failure etiologies in weaned patients included toxic (recreational drugs) (n = 8, 57%), toxic (medication) (n = 2, 14%), ischemic (n = 2, 14%), or idiopathic dilated (n = 2, 14%) cardiomyopathy. In unweaned patients, heart failure was mostly attributed to ischemic (n = 35, 42%) and idiopathic dilated (n = 27, 32%) cardiomyopathy. Three months after implantation, patients who were eventually weaned had a higher LV ejection fraction (LVEF) (35% vs 19%, P = 0.001) and lower left ventricular end-diastolic diameter (LVEDD) (52 vs 60 mm, P = 0.03) than unweaned patients. At last follow-up after weaning, mean LVEF was 44 ± 6% and no death nor heart transplant had occurred. LVADs can induce LV reverse remodeling leading to myocardial recovery in a significant proportion of patients, especially those with toxic and nonischemic cardiomyopathies. Early reverse remodeling with decreasing LVEDD and improving LVEF at 3 months after implantation may suggest potential candidacy for LVAD weaning. Weaned patients maintain satisfactory LVEF recovery after weaning and have good long-term event-free survival.

3 July 2025 in CJC Open
Verified
Journal Article
Open access
MBMarie-Christine Blais
Marie-Christine Blais
ACAlexandre Cinq-Mars
Alexandre Cinq-Mars
ÉVÉmile Voisine
Émile Voisine
RSRoxanne St-Louis
Roxanne St-Louis
CPCharline Pujos
Charline Pujos
MSMario Senechal
Mario Senechal
Aortic valve replacement (AVR) for chronic aortic regurgitation (AR) in the presence of reduced left ventricular ejection fraction (LVEF) is associated with greater surgical risk. Long-term outcomes remain poorly described in contemporary cohorts. Between 2004 and 2019, 122 patients underwent AVR for chronic severe AR with LVEF < 50%. Patients with severely reduced LVEF (< 35%; n = 37) were compared with those with mild to moderately reduced LVEF (35%-50%; n = 85). Preoperative and intraoperative characteristics were similar in both groups. Operative mortality for the entire cohort was 1.6% (n = 2) and similar across the LVEF spectrum. Postoperatively, optimal medical therapy was achieved in most patients and > 25% of patients with LVEF < 35% benefited from cardiac resynchronization therapy. At latest follow-up, mean LVEF was 42 ± 12% in the severely reduced LVEF group (vs baseline 28 ± 5%; P < 0.001) and 51 ± 9% in the mild to moderately reduced LVEF group (vs baseline 46 ± 4%; P < 0.001). Freedom from cardiovascular death at 10 years was 87.2% in the severe group and 94.7% in the mild to moderate group (P = 0.10). Freedom from heart failure hospitalization at 10 years was higher in the mild to moderate group (96.3%) than in the severe group (88.3%; P = 0.009). In this contemporary cohort of patients who underwent AVR for chronic severe AR, patients with severely reduced LVEF treated with optimal medical therapy had operative mortality and freedom from cardiovascular death similar to patients with mild to moderately reduced LVEF. Favourable left ventricular remodelling was observed in both groups. Hospitalization for heart failure was < 15% in both groups at 10-year follow-up.

21 August 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
EVEmile Voisine
Emile Voisine
MSMario Sénéchal
Mario Sénéchal
Click on the article title to read more.

17 August 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
EVEmile Voisine
Emile Voisine
MSMario Sénéchal
Mario Sénéchal